Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Baricitinib (INCB28050,LY3009104)
Cat No.
CEI-0198
Description
Baricitinib (INCB28050, LY3009104) can inhibit JAK1 and JAK2 with IC50 of 5.9 nM and 5.7 nM.
Alias
INCB 28050
CAS No.
1187594-09-7
Molecular Weight
371.41688
Purity
>99%
Storage
2 years at -20centigrade Powder
Synonyms
INCB 28050
Targets
JAK1, JAK2
Molecular Formula
C16H17N7O2S
Chemical Name
3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
Solubility
DMSO 74 mg/mL Water
In vitro
As an ATP competitive kinase inhibitor, INCB028050 (Baricitinib, LY3009104) was a potent inhibitor of JAK1 and JAK2 with IC50 values of 5.9 and 5.7 nM, respectively. INCB0-28050 (Baricitinib, LY3009104), a potent and selective inhibitor of JAK1/2, is shown to inhibit signaling from pathogenic cytokines such as IL-6 and IL-23. Inhibition of JAK signaling prevents the production of chemokines and cytokines associated with uncontrolled RA. In cell-based assays, INCB028050 proved to be a potent inhibitor of JAK signaling and function. In PBMCs, INCB028050 inhibited IL-6-stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) and subsequent production of the chemokine MCP-1 with IC50 values of 44 nM and 40 nM, respectively. In isolated naive T-cells, INCB028050 also inhibited pSTAT3 stimulated by IL-23 (IC 50 = 20 nM).
Download
Download Datasheet